Article Text

PDF
Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye
  1. B R Kosobucki,
  2. W R Freeman,
  3. L Cheng
  1. Joan and Irwin Jacobs Retina Center, Department of Ophthalmology, Shiley Eye Center, University of California, San Diego, 9415 Campus Point Drive, La Jolla, CA 92093-0946, USA
  1. Correspondence to: William R Freeman MD, Joan and Irwin Jacobs Retina Center, Department of Ophthalmology, Shiley Eye Center, University of California, San Diego, 9415 Campus Point Drive, La Jolla, CA 92093-0946, USA; freeman{at}eyecenter.ucsd.edu

Abstract

Aim: To determine the duration of residence of triamcinolone in the vitrectomised eye.

Methods: 23 eyes of 23 patients underwent intravitreal injection of high dose (20 mg) decanted triamcinolone acetonide (Kenalog) at the conclusion of vitrectomy surgery or in previously vitrectomised eyes with macular oedema from diabetes, uveitis, cataract surgery, or other surgery.

Results: The median time to disappearance of triamcinolone in the vitrectomised eye was 113 days (95% confidence interval (CI) 85 to 191). In the phakic eyes the median time to disappearance was 191 days (95% CI 148 to 191). In the pseudophakic eyes the median time to disappearance was 102 days (95% CI 85 to 113). This difference was not significant (p = 0.12). There were no cases of endophthalmitis or severe inflammatory reaction. Five eyes (22%) experienced intraocular pressure rise ⩾10 mm Hg.

Conclusions: High dose decanted intravitreal triamcinolone has a median residence time of 113 days in the vitrectomised eye. Although this appears to be shorter than in the non-vitrectomised eye, this study suggests that a sufficient duration of action will be present to be clinically useful.

  • ARMD, age related macular degeneration
  • IOP, intraocular pressure
  • POAG, primary open angle glaucoma
  • diabetes
  • macular degeneration
  • macular oedema
  • triamcilone
  • vitreous injection
  • ARMD, age related macular degeneration
  • IOP, intraocular pressure
  • POAG, primary open angle glaucoma
  • diabetes
  • macular degeneration
  • macular oedema
  • triamcilone
  • vitreous injection

Statistics from Altmetric.com

Footnotes

  • Sponsoring organisation: NIH EYO 7366 (WRF).

  • Proprietary interests: none.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • BJO at a glance
    Creig Hoyt